JMP Securities maintains Cytokinetics stock with $78 target
JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...
JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...
JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.